Abemaciclib 100 mg tab and imlunestrant 200 mg were FDA-approved based on the Phase 3 EMBER-3 trial.
Jhaveri K, Neven P, Casalnuovo M , Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial. Annals of Oncology, 2025; 37, 532-543
Inluriyo Prescribing Information 2026
Cancer Treatment Today
228 Park Ave S #70464
New York, NY 10003-1502
info@cancertreatmenttoday.org
Tel - 212-372-7263